XML 91 R31.htm IDEA: XBRL DOCUMENT
v3.19.3

Mezzanine and Stockholders' Equity (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2019
Stockholders' Equity Note [Abstract] |
Stock Option Transactions Under Stock Option Plans | The Company’s outstanding stock options consisted of the following:
| Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term (Years) |  | Aggregate Intrinsic Value (in millions)
Options outstanding at January 1, 2019 | 647,240 |  |  | $ | 5.62 |  |  | 4.13 |  |  | $ | 9.2 |
Options granted | 123,378 |  |  | 17.80 |  |  | — |  |  | — |
Options exercised | (203,524 | ) |  | 5.77 |  |  | — |  |  | 2.4 |
Options forfeited | — |  |  | — |  |  | — |  |  | — |
Options outstanding at September 30, 2019 | 567,094 |  |  | $ | 8.22 |  |  | 3.60 |  |  | $ | 5.4 |
Options exercisable at September 30, 2019 | 466,216 |  |  | $ | 5.07 |  |  | 2.74 |  |  | $ | 5.3 |
Outstanding stock options granted to primary care physicians to purchase shares of APC’s common stock consisted of the following:
| Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term (Years) |  | Aggregate Intrinsic Value (in millions)
Options outstanding at January 1, 2019 | 853,800 |  |  | $ | 0.167 |  |  | 0.75 |  |  | $ | 0.5 |
Options granted | — |  |  | — |  |  | — |  |  | — |
Options exercised | — |  |  | — |  |  | — |  |  | — |
Options expired/forfeited | — |  |  | — |  |  | — |  |  | — |
Options outstanding and exercisable at September 30, 2019 | 853,800 |  |  | $ | 0.167 |  |  | 0.00 |  |  | $ | 0.5 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions | During the nine months ended September 30, 2019, the Company granted 45,000 and 78,378 five year stock options to certain ApolloMed board members and executives, with exercise price of $18.11 and $17.62, respectively, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:
September 30, 2019 | Board Members |  | Executives
Expected Term | 3.0 years |  |  | 4.0 years |
Expected volatility | 100.27 | % |  | 91.04 | %
Risk-free interest rate | 2.51 | % |  | 1.55 | %
Market value of common stock | $ | 18.11 |  |  | $ | 17.62 |
Annual dividend yield | — | % |  | — | %
Forfeiture rate | 0 | % |  | 0 | %
Summary of Share-Based Compensation Expense of Stock Option Awards Granted | Share-based compensation expense related to option awards granted to primary care physicians to purchase shares of APC’s common stock, are recognized over their respective vesting periods, and consisted of the following:
| Three Months Ended September 30,
| 2019 |  | 2018
Share-based compensation expense: |  |  |
General and administrative | $ | 202,382 |  |  | $ | 202,382 |
| $ | 202,382 |  |  | $ | 202,382 |
| Nine Months Ended September 30,
| 2019 |  | 2018
Share-based compensation expense: |  |  |
General and administrative | $ | 607,146 |  |  | $ | 607,146 |
| $ | 607,146 |  |  | $ | 607,146 |
Warrants Outstanding | The Company’s outstanding warrants consisted of the following:
| Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term (Years) |  | Aggregate Intrinsic Value (in millions)
Warrants outstanding at January 1, 2019 | 3,331,995 |  |  | $ | 9.93 |  |  | 2.97 |  |  | $ | 33.1 |
Warrants granted | — |  |  | — |  |  | — |  |  | — |
Warrants exercised | (133,221 | ) |  | 9.21 |  |  | — |  |  | 1.4 |
Warrants expired/forfeited | — |  |  | — |  |  | — |  |  | — |
Warrants outstanding at September 30, 2019 | 3,198,774 |  |  | $ | 9.96 |  |  | 2.26 |  |  | $ | 24.5 |
Exercise Price Per Share |  | Warrants Outstanding |  | Weighted Average Remaining Contractual Life |  | Warrants Exercisable |  | Weighted Average Exercise Price Per Share
$ | 9.00 |  |  | 971,165 |  |  | 1.04 |  | 971,165 |  |  | $ | 9.00 |
10.00 |  |  | 1,399,667 |  |  | 2.55 |  | 1,399,667 |  |  | 10.00 |
11.00 |  |  | 827,942 |  |  | 3.19 |  | 827,942 |  |  | 11.00 |
$ 9.00 –11.00 |  |  | 3,198,774 |  |  | 2.26 |  | 3,198,774 |  |  | $ | 9.96 |

X
- Definition Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration